Peer-reviewed veterinary case report
Doxorubicin with cyclophosphamide for treating canine lymphoma
By Lori, J C et al.·Published in Veterinary and comparative oncology·2010·Colorado State University College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study.
- Species:
- dog
Plain-English summary
A group of dogs with advanced lymphoma (a type of cancer) was treated with a combination of two chemotherapy drugs, doxorubicin and cyclophosphamide, to see if it would help them live longer. The dogs received doxorubicin every three weeks along with prednisone for the first month. While the combination treatment was well tolerated and did not cause more side effects than doxorubicin alone, it did not significantly improve survival times compared to those receiving doxorubicin with a placebo. Overall, the dogs showed some improvement, but the addition of cyclophosphamide did not lead to a clear benefit in their treatment outcomes.
People also search for: dog lymphoma treatment options · doxorubicin side effects in dogs · canine cancer survival rates
Abstract
Median survival times (STs) for doxorubicin-treated canine lymphoma range from 5.7 to 9 months. Because dogs treated with multi-agent protocols have longer STs, we sought to evaluate whether adding cyclophosphamide would improve outcome in canine lymphoma patients while maintaining an acceptable level of toxicity. Thirty-two dogs with stage III-V multicentric lymphoma were treated with doxorubicin every 3 weeks for five total cycles and prednisone at a tapering dose for the first 4 weeks. Dogs were randomized to receive either cyclophosphamide or placebo concurrently. Seventeen dogs received doxorubicin and placebo, while 15 dogs received doxorubicin and cyclophosphamide. Response, toxicity, progression-free interval (PFI) and ST were evaluated. The combination of doxorubicin and cyclophosphamide was well tolerated, causing no increase in adverse events over doxorubicin alone. Despite a numeric improvement in outcome in cyclophosphamide treated dogs, the addition of cyclophosphamide did not result in statistically improved response rate, PFI or ST.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20691026/